VNDA vs. RIGL, VSTM, GOSS, XOMA, RGLS, EBS, LXRX, VBIV, ANAB, and OPK
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Gossamer Bio (GOSS), XOMA (XOMA), Regulus Therapeutics (RGLS), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), VBI Vaccines (VBIV), AnaptysBio (ANAB), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Rigel Pharmaceuticals has a consensus price target of $5.81, indicating a potential upside of 428.41%. Given Rigel Pharmaceuticals' higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Vanda Pharmaceuticals.
Vanda Pharmaceuticals received 84 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 68.55% of users gave Vanda Pharmaceuticals an outperform vote.
In the previous week, Vanda Pharmaceuticals had 10 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 0 mentions for Rigel Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.51 beat Rigel Pharmaceuticals' score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Vanda Pharmaceuticals has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Vanda Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vanda Pharmaceuticals has a net margin of 1.30% compared to Rigel Pharmaceuticals' net margin of -21.47%. Vanda Pharmaceuticals' return on equity of 0.46% beat Rigel Pharmaceuticals' return on equity.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Vanda Pharmaceuticals beats Rigel Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
